Clinical Trial Update: Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial indicates that prophylaxis with ganciclovir improves graft survival in renal transplant recipients by preventing cytomegalovirus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: Lower Saxony Center for Nephrology | Conditions: DNA Virus Infection, Herpesviridae Infections | Phase 4 | Status: COMPLETED